Benign Conditions

Henry Rosevear, MD, discusses the ten things he’d like to see happen in 2017 for the field of urology.

Percutaneous nephrolithotomy in the presence of aspirin appears both effective and safe. In a retrospective review of almost 300 PCNL cases, postoperative hemorrhage was uncommon in patients who continued aspirin preoperatively, said Brandon Otto, MD, at the AUA annual meeting in San Diego.

Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.

“Our research shows that the implications of kidney stones may go beyond the discomfort they are so often associated with,” says co-lead author Andrew Rule, MD.

. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections

Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.

Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.

Bilateral replacement of the uterosacral ligaments with a polyvinylidene fluoride (PVDF) mesh (DynaMesh, FEG Textiltechnik mbH) is more effective than medical treatment with solifenacin (Vesicare) for achieving continence in women with urgency urinary incontinence (UUI) associated with only minor pelvic organ prolapse, according to the interim results of a prospective, randomized, crossover clinical trial.

A new laboratory study suggests that a widely available nutritional supplement has potential to become a new treatment for the wide majority of kidney stones. Clinical research is still pending, however, and there are important caveats about the findings.

After meeting its primary endpoint at 3 months in a prospective, randomized, sham-controlled clinical trial, an intravesical pressure-attenuation balloon (Vesair Bladder Control System, Solace Therapeutics) for treatment of female stress urinary incontinence demonstrated durable efficacy and safety after 12 months of follow-up.

In this video, Dr. Nicholas Kavoussi sits down with Dr. Arthur L. Burnett, II, of the Urology Times Editorial Council to discuss his 2016 AUA presentation, "Preoperative urine cultures for prosthetic urological surgery: What is the evidence?"

A new meta-analysis links moderate-to-severe lower urinary tract symptoms (LUTS) to heart disease in men, possibly because unhealthy lifestyles boost the risks of both conditions.

"LUTS is an important health care burden, and health care professionals should be screening for its presence in men at risk," writes Steven A. Kaplan, MD.

A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.

This article provides an update on the risk factors for stone disease and its presentation in children, and offers practical tips on its evaluation, treatment, and prevention.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

Other female urology topics discussed at this year's AUA meeting include preoperative urodynamics for women undergoing prolapse surgery and a study on nocturia.

Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.

Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.

Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.

Other key stone disease/endourology topics from the 2016 AUA annual meeting included the use of aspirin in percutaneous nephrolithotomy patients as well as the continuing debate over the benefit of medical expulsive therapy.

In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.

This video demonstrates UroLift placement under topical anesthesia in the office setting and also includes comments from several patients who underwent the procedure.

This video provides an overview of the prostatic urethral lift (UroLift), highlighting the entire cycle of patient care.

Although there is no clear-cut solution to the problem of recurrent UTIs in postmenopausal women, "various strategies can be employed that have found success," write Wade Bushman, MD, PhD, and Brian V. Le, MD, MA.

A recent study provides the first comprehensive catalog of urinary calcium oxalate monohydrate binding proteins.

Researchers from the Endourology Disease Group for Excellence research consortium compared the techniques in 152 patients at several stone centers.

Trends in percutaneous nephrolithotomy may reflect other stone treatment trends, study authors say.

An image-guided technique for treating LUTS associated with BPH is reproducible and promising, researchers say.

A new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.